Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide

Journal of the National Cancer Institute
C L ChenM V Relling

Abstract

Etoposide, an inhibitor of the normal religation activity of the nuclear enzyme topoisomerase II, can induce a secondary acute myeloid leukemia characterized by site-specific DNA rearrangements. The schedule of drug administration appears to be a clinical risk factor for this devastating treatment complication. We tested the hypothesis that prolonged exposure of leukemia cells in vitro to low concentrations of etoposide, compared with short exposures to high concentrations, could produce equivalent or greater desired cytotoxic effects, with decreased occurrence of undesired site-specific double-stranded DNA recombinational events (i.e., recombinogenesis). We used the frequency of V(D)J (variable-diversity-joining) recombinase-mediated deletions of exons 2 and 3 of the hypoxanthine phosphoribosyltransferase (HPRT) gene as a biomarker of etoposide-induced, nonhomologous, site-specific DNA rearrangement. A polymerase chain reaction-based technique was used to measure exon 2 + 3 deletions in human lymphoid leukemia CCRF-CEM cells 6 days after either 4-hour or 24-hour treatment with etoposide at clinically relevant concentrations. Cytotoxic effects of etoposide (determined by the number of viable cells present in the treated compare...Continue Reading

Citations

Jan 15, 2009·Genetica·L P G D'ArceE T Sakamoto-Hojo
Jun 10, 2000·British Journal of Haematology·C H Pui, M V Relling
Aug 2, 2012·International Journal of Environmental Research and Public Health·Sachiko Ezoe
Apr 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hai XiaoLeroy F Liu
Apr 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·R StrickJ D Rowley
May 30, 2001·Leukemia & Lymphoma·G LeoneL Pagano
Jun 20, 2014·International Journal of Cancer. Journal International Du Cancer·Daniel K ChoiNobuko Hijiya
Jan 10, 2018·Dermatologic Therapy·Seda PurnakLawrence Aaron Mark
Nov 9, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Justin H GundelachRichard J Bram
May 13, 2018·International Journal of Urology : Official Journal of the Japanese Urological Association·Yuta InoueOsamu Ukimura
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A SmithD Vena
Sep 28, 1998·Biochimica Et Biophysica Acta·B C Baguley, L R Ferguson
Jan 31, 2002·Journal of Chromatography. B, Biomedical Sciences and Applications·C L ChenF M Uckun
Sep 28, 1998·Biochimica Et Biophysica Acta·C A Felix

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.